Results 291 to 300 of about 137,002 (346)
Some of the next articles are maybe not open access.
Lipid effects of glucagon-like peptide 1 receptor analogs
Current Opinion in Lipidology, 2021Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming more prominent as a therapeutic choice in diabetes management and their use is being expanded to other indications, such as obesity. Dyslipidemia and cardiovascular disease are common co-morbidities in these populations and understanding the ...
Amanda J, Berberich, Robert A, Hegele
openaire +2 more sources
Diabetes, obesity and metabolism, 2023
To determine the potential association between the use of either glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) or dipeptidyl peptidase‐4 (DPP‐4) inhibitors, and the risk of thyroid cancer in individuals with type 2 diabetes.
S. Bea +5 more
semanticscholar +1 more source
To determine the potential association between the use of either glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) or dipeptidyl peptidase‐4 (DPP‐4) inhibitors, and the risk of thyroid cancer in individuals with type 2 diabetes.
S. Bea +5 more
semanticscholar +1 more source
Overview of Glucagon-like Peptide-1 Receptor Agonists
Home Healthcare Now, 2015Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman +2 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...Heather P. Whitley, Jennifer M. Trujillo
+4 more sources
Renal protection with glucagon-like peptide-1 receptor agonists
Current Opinion in Pharmacology, 2020There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M. +3 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
Trends in Endocrinology & Metabolism, 2016Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on ...
van Raalte, Daniël H, Verchere, C Bruce
openaire +4 more sources
Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults
JAMA Network OpenThis economic evaluation estimates annual total US spending on glucagon-like peptide-1 receptor agonists from 2018 to 2023.
Stavros Tsipas +4 more
semanticscholar +1 more source
Obesity, 2022
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists recently demonstrated 15% to 20% weight loss in adults with obesity, a range which has previously been achieved only with bariatric surgery.
Shohinee Sarma, Patricia Palcu
semanticscholar +1 more source
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists recently demonstrated 15% to 20% weight loss in adults with obesity, a range which has previously been achieved only with bariatric surgery.
Shohinee Sarma, Patricia Palcu
semanticscholar +1 more source
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Science Translational Medicine, 2018An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach. Assisting absorption Glucagon-like peptide-1 receptor agonists can help treat type 2 diabetes but must be ...
S. Buckley +21 more
semanticscholar +1 more source
Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
Diabetes, obesity and metabolismTo assess whether adults with diabetes on oral hypoglycaemic agents undergoing general endotracheal anaesthesia during nine common surgical procedures who are glucagon‐like peptide‐1 receptor agonist (GLP1‐RA) users, compared with non‐users, are at ...
D. Klonoff +8 more
semanticscholar +1 more source